Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017–2018 influenza season

Abstract

a b s t r a c tPurpose: Receiving influenza vaccination may increase the risk of other respiratory viruses, a phenomenon known as virus interference. Test-negative study designs are often utilized to calculate influenza vaccine effectiveness. The virus interference phenomenon goes against the basic assumption of the test-negative vaccine effectiveness study that vaccination does not change the risk of infection with other respiratory illness, thus potentially biasing vaccine effectiveness results in the positive direction. This study aimed to investigate virus interference by comparing respiratory virus status among Department of Defense personnel based on their influenza vaccination status. Furthermore, individual respiratory viruses and their association with influenza vaccination were examined. Results: We compared vaccination status of 2880 people with non-influenza respiratory viruses to 3240 people with pan-negative results. Comparing vaccinated to non-vaccinated patients, the adjusted odds ratio for non-flu viruses was 0.97 (95% confidence interval (CI): 0.86, 1.09; p = 0.60). Additionally, the vaccination status of 3349 cases of influenza were compared to three different control groups: all controls (N = 6120), non-influenza positive controls (N = 2880), and pan-negative controls (N = 3240). The adjusted ORs for the comparisons among the three control groups did not vary much (range: 0.46-0.51). Conclusions: Receipt of influenza vaccination was not associated with virus interference among our population. Examining virus interference by specific respiratory viruses showed mixed results. Vaccine derived virus interference was significantly associated with coronavirus and human metapneumovirus; however, significant protection with vaccination was associated not only with most influenza viruses, but also parainfluenza, RSV, and non-influenza virus coinfections.Published by Elsevier Ltd.

Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative design

“…A recent study has suggests that SARS-CoV-2 has a lower growth rate than influenza and is suppressed if the infections start simultaneously, however, if an influenza infection were to occur after SARS-CoV-2 infection, a coinfection would be detected 24 . Our findings would not support the relaxation of preventative measures against influenza, including vaccination, given the risk of morbidity and mortality from influenza 5,25,26 as well as our finding of adverse outcomes associated with influenza and SARS-CoV-2 coinfection. Furthermore, results from Brazil indicated a significantly lower odds of needing intensive care treatment, invasive respiratory support and death among patients with SARS-CoV-2 that received the inactivated trivalent influenza vaccine…”

Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study

“…Although our findings do not allow for assumptions to be made about the mechanisms underlying the putative protective role of influenza vaccination on COVID-19 outcomes, previous immunological and epidemiological studies [35][36][37][38][39], as well as mathematical models [40][41][42], support the concept that vaccination against one microorganism may affect the host's response to other infectious agents. For example, vaccination against mycobacterium tuberculosis with the bacillus Calmette-Guérin vaccine significantly increases the secretion of IL-1B (a pro-inflammatory cytokine), which plays a recognized role in antiviral immunity [43].…”

The association between influenza vaccination and the risk of SARS-CoV-2 infection, severe illness, and death: a systematic review of the literature

“…season, much earlier the emergence of the SARS-CoV-2 virus [18]. After reviewing the existing literature on the topic, we can safely conclude that influenza vaccination is unlikely to be associated with an increase in SARS-CoV-2 risk of infection or with COVID-19 severity and the risk of associated death.…”